IORD proposes a Section 8, CSR-supported public-interest pharmaceutical model to ensure affordable access to orphan drugs for millions of Indian patients.
Blog
IORD highlights India’s rare disease crisis, with Prof. Ramaiah Muthyala urging grassroots solutions to improve access, awareness, and care for millions affected nationwide.
IORD CEO & President Dr. Ramaiah Muthyala provides insights on advancing rare disease awareness in India, stressing early diagnosis, frontline healthcare training, and integration into public health systems.
IORD highlights gaps in rare disease care, with Prof. Ramaiah Muthyala noting progress under NPRD but stressing persistent challenges in diagnosis, treatment, and need for disease-specific strategies.